SyriMed recalls Baclofen oral solution due to crystallisation issues
Syri Limited is recalling Baclofen 10mg/5ml oral solution due to crystallisation observed over time.
Published: June 24, 2026
Updated: June 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Muscle Relaxant
Asset: Baclofen
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Baclofen
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The recall of Baclofen oral solution due to crystallisation issues raises safety concerns that could influence prescriber and patient confidence. This situation presents an opportunity for competitors to gain market share if they can effectively address these concerns.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for updates on the recall process and any potential regulatory actions or competitor responses.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.